📰 Ohio Engine News
Page 2 - Ohio Engine News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ohio Engine. Real-time updates on events, politics, business and more.
October 4, 2023
Ford Motor Company (NYSE:F) has made its seventh offer to the United Auto Workers, which the automaker called its “strongest” proposal to date. The...
October 3, 2023
InlandNewsToday is the one-stop online source for same-day news and events occurring in Riverside and San Bernardino counties in Southern California featuring news, traffic information, real-time weather and things to do, all this offered in text and webcasts/podcasts.
October 3, 2023
General Motors and Ford Motor plan to reduce their workforce by 500 employees due to the ongoing United Auto Workers strike.
October 3, 2023
On Monday, General Motors (NYSE: GM) and Ford Motor (NYSE: F) revealed they will be laying off 500 workers from four of their Midwestern facilities as yet another consequence of the unprecedented UAW strike that kicked off on September 15th.
October 3, 2023
Job openings in the U.S. unexpectedly showed a notable increase in the month of August, the Labor Department revealed in a report released on Tuesday. The Labor Department said job openings surged to 9.
October 3, 2023
(RTTNews) - General Motors and Ford Motor reportedly said they are furloughing 500 more workers at four plants hit by the ongoing strike by United...
October 3, 2023
Earthstone Energy, Inc. (ESTE) announced Tuesday the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended, with respect to the previously-announced agreement for Permian Resources Corp.
October 3, 2023
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
October 3, 2023
General Motors Company (NYSE:GM) and Ford Motor Company (NYSE:F) each announced worker furloughs in connection with the United Auto Workers (UAW) strike on...
October 3, 2023
Kineta, Inc. (KA) announced an update on its ongoing Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123 cleared the first three monotherapy dose levels and was well tolerated with no dose limiting toxicities or cytokine related adverse events observed.